| Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management (NCT00801892) | Eileen R. Chasens | 2009-04-01 |
| A Study of LY2405319 in Participants With Type 2 Diabetes (NCT01869959) | Eli Lilly and Company | 2009-04-01 |
| Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes (NCT00849563) | Duke University | 2009-04-01 |
| Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers (NCT00933062) | GlaxoSmithKline | 2009-03-23 |
| Pilot Study of a Self-help Intervention for Depression in Patients With a Chronic Disease (NCT00854984) | University of Edinburgh | 2009-03-13 |
| Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension (NCT00881530) | Boehringer Ingelheim | 2009-03-01 |
| Effect of Inpatient Diabetes Management on Outpatient Glycemic Control (NCT00869362) | Massachusetts General Hospital | 2009-03-01 |
| A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh (NCT00839878) | Novo Nordisk A/S | 2009-03-01 |
| A Study for Participants With Type 2 Diabetes Mellitus (NCT00871572) | Eli Lilly and Company | 2009-03-01 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) (NCT00866658) | Sanofi | 2009-03-01 |
| The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes (NCT00856986) | Novo Nordisk A/S | 2009-03-01 |
| Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir (NCT00873223) | Novo Nordisk A/S | 2009-03-01 |
| A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235) (NCT01357148) | Merck Sharp & Dohme LLC | 2009-03-01 |
| Effect of Renal Impairment on the Pharmacokinetics of NN9535 (NCT00833716) | Novo Nordisk A/S | 2009-02-02 |
| Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment (NCT00865397) | Novo Nordisk A/S | 2009-02-01 |
| Diabetes Connect: Patients and Providers Use of a Secure Website for Blood Glucose Monitoring in Type-2 Diabetes (NCT00812539) | Massachusetts General Hospital | 2009-02-01 |
| Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea (NCT02090673) | AstraZeneca | 2009-02-01 |
| Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease (NCT00849316) | Novo Nordisk A/S | 2009-02-01 |
| Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China (NCT02040246) | RenJi Hospital | 2009-02-01 |
| A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234) (NCT01354990) | Merck Sharp & Dohme LLC | 2009-02-01 |
| A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes (NCT00838916) | GlaxoSmithKline | 2009-02-01 |
| Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes (NCT00838903) | GlaxoSmithKline | 2009-02-01 |
| Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes (NCT00860288) | Novartis Pharmaceuticals | 2009-02-01 |
| A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus (NCT00882726) | Centocor, Inc. | 2009-02-01 |
| A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes (NCT00853151) | Eli Lilly and Company | 2009-02-01 |
| A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes (NCT00839527) | GlaxoSmithKline | 2009-02-01 |
| Evaluating a Web-Based Cardiovascular Disease Risk Factor Reduction Program Among American Indians (NCT00608387) | Black Hills Center for American Indian Health | 2009-02-01 |
| Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia (NCT02305355) | Kuhnil Pharmaceutical Co., Ltd. | 2009-02-01 |
| Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs (NCT00819741) | Novo Nordisk A/S | 2009-02-01 |
| Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (NCT00841048) | AstraZeneca | 2009-02-01 |
| A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus (NCT00800176) | Hoffmann-La Roche | 2009-01-22 |
| A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers (NCT00938275) | Sirtris, a GSK Company | 2009-01-20 |
| A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects (NCT00823940) | GlaxoSmithKline | 2009-01-13 |
| Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals (NCT00813228) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2009-01-06 |
| Management of Type 2 Diabetes After Gastric Bypass Surgery (NCT01213563) | Imperial College London | 2009-01-01 |
| Safety and Efficacy Study of Albiglutide in Type 2 Diabetes (NCT00849017) | GlaxoSmithKline | 2009-01-01 |
| Orthostatic Hypotension and Diabetes Mellitus (NCT00807976) | Medical Research Foundation, The Netherlands | 2009-01-01 |
| Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir® (NCT00806897) | Novo Nordisk A/S | 2009-01-01 |
| Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes (NCT00949091) | Takeda | 2009-01-01 |
| Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes (NCT01935804) | King Abdulaziz University | 2009-01-01 |
| Safety and Efficacy of Albiglutide in Type 2 Diabetes (NCT00849056) | GlaxoSmithKline | 2009-01-01 |
| A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore (NCT00836030) | Novo Nordisk A/S | 2009-01-01 |
| Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Type 2 Diabetic Patients (NCT00806975) | Nagaoka Red Cross Hospital | 2009-01-01 |
| Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus (NCT00842361) | Novo Nordisk A/S | 2009-01-01 |
| A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy (NCT00823992) | Hoffmann-La Roche | 2009-01-01 |
| Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D (NCT01585051) | Kantonsspital Baselland Bruderholz | 2009-01-01 |
| Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus (NCT01902316) | Beijing Institute of Technology | 2009-01-01 |
| Physical and Chemical Study of Atherosclerosis Mechanisms (NCT01700075) | Nazarbayev University | 2009-01-01 |
| Telerehabilitation Intervention to Promote Exercise for Diabetes (NCT00334113) | US Department of Veterans Affairs | 2009-01-01 |
| Type 2 Diabetes Haptoglobin Phenotype and Vitamin E (NCT01113671) | Technion, Israel Institute of Technology | 2009-01-01 |
| Type 2 Diabetes Prevention (NCT02542722) | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 2009-01-01 |
| A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects (NCT00813020) | Novo Nordisk A/S | 2009-01-01 |
| A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED) (NCT00873821) | Merck Sharp & Dohme LLC | 2008-12-01 |
| Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive (NCT00800683) | Boehringer Ingelheim | 2008-12-01 |
| Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug (NCT00819091) | Boehringer Ingelheim | 2008-12-01 |
| A Study for Patients With Type 2 Diabetes Mellitus (NCT00804986) | Eli Lilly and Company | 2008-12-01 |
| A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand (NCT00805922) | Novo Nordisk A/S | 2008-12-01 |
| Response To Oral Agents in Diabetes (ROAD)- Pilot Study (NCT00780715) | University of Dundee | 2008-12-01 |
| Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects (NCT00806936) | Novo Nordisk A/S | 2008-12-01 |
| A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes (NCT00809705) | Hoffmann-La Roche | 2008-12-01 |
| Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes (NCT00807092) | Novo Nordisk A/S | 2008-12-01 |
| Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes (NCT00791479) | Eli Lilly and Company | 2008-12-01 |
| Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design (NCT00798161) | Boehringer Ingelheim | 2008-12-01 |
| Observational Study on Levemir® in Obese Diabetic Patients (NCT00849342) | Novo Nordisk A/S | 2008-12-01 |
| A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects (NCT00937872) | Sirtris, a GSK Company | 2008-11-22 |
| Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus (NCT00806858) | Novo Nordisk A/S | 2008-11-01 |
| Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (NCT00869908) | Novo Nordisk A/S | 2008-11-01 |
| Lifestyle Intervention For Effective Diabetes Management (NCT00813930) | Unity Health Toronto | 2008-11-01 |
| A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia (NCT00788853) | Novo Nordisk A/S | 2008-11-01 |
| Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes (NCT00821977) | Novartis | 2008-11-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers (NCT00910923) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-11-01 |
| A Study of Taspoglutide in Type 2 Diabetic Patients (NCT00811460) | Hoffmann-La Roche | 2008-11-01 |
| Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes. (NCT00793273) | Novo Nordisk A/S | 2008-11-01 |
| Comparison of Nutritional Products for People With Type 2 Diabetes (NCT00797069) | Abbott Nutrition | 2008-11-01 |
| Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes (NCT00789191) | Novo Nordisk A/S | 2008-11-01 |
| An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes (NCT00789711) | Novo Nordisk A/S | 2008-11-01 |
| A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea. (NCT00755287) | Hoffmann-La Roche | 2008-11-01 |
| Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients (NCT00751114) | Sanofi | 2008-11-01 |
| A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus. (NCT00790660) | Astellas Pharma Inc | 2008-10-23 |
| Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED) (NCT00767000) | Merck Sharp & Dohme LLC | 2008-10-01 |
| A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone. (NCT00744367) | Hoffmann-La Roche | 2008-10-01 |
| Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin (NCT00775736) | Novo Nordisk A/S | 2008-10-01 |
| Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes (NCT00771680) | Novo Nordisk A/S | 2008-10-01 |
| Variation in Serum Levels of Metformin in Patients With Reduced Renal Function (NCT00767351) | Skane University Hospital | 2008-10-01 |
| Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK (NCT00995995) | GlaxoSmithKline | 2008-10-01 |
| A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics (NCT00886821) | Pfizer | 2008-10-01 |
| A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. (NCT00754988) | Hoffmann-La Roche | 2008-10-01 |
| 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients (NCT00789035) | Boehringer Ingelheim | 2008-10-01 |
| Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake (NCT00747006) | Mannkind Corporation | 2008-09-01 |
| Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) (NCT00770081) | Novartis | 2008-09-01 |
| Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes (NCT00754689) | Sanofi | 2008-09-01 |
| Observational Study on Safety of Self-titration of Once Daily Levemir® (NCT00740519) | Novo Nordisk A/S | 2008-09-01 |
| Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics (NCT00773279) | Novo Nordisk A/S | 2008-09-01 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (NCT00763451) | Sanofi | 2008-09-01 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (NCT00763815) | Sanofi | 2008-09-01 |
| Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months (NCT00755833) | Novo Nordisk A/S | 2008-09-01 |
| Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2 (NCT01512654) | University Hospital, Montpellier | 2008-09-01 |
| Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes (NCT00728403) | Unity Health Toronto | 2008-09-01 |
| How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine? (NCT00749047) | Christchurch Hospital | 2008-09-01 |
| Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension) (NCT00765830) | Novartis | 2008-09-01 |